NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
Executive Summary
With the same range of novel product submissions as in 2011, the year ahead could reach an equally healthy tally of new molecular and novel biological entity approvals. But a look at upcoming applications suggests that the makeup of those classes could be very different.
You may also be interested in...
LEO Plays Up Rapid Action Of Picato For Actinic Keratosis
Newly approved plant-based gel works in just a few days of treatment, rather than the weeks required for some competitors.
Revelations And Resolutions, In Brief
News about Inhibitex, Gilenya, Genzyme manufacturing, Forest's linaclotide, and Paula Deen
Dapagliflozin Faces Ominous Prospect Of New Trials
FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.